RCUS
Arcus Biosciences Inc
24.90$
-0.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
Arcus Biosciences Inc (RCUS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -119 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13 | -9.6 | -6.8 | -24 | 16 | -13 | -11 | -12 | -7.1 | -17 | -20 | -27 | -9.5 | -31 | -24 | 216 | -50 | -66 | -74 | -54 | -62 | 654 | -65 | -81 | -70 | -98 | -57 | -63 | -88 | -2.0 | -94 | 26 | -100 | -132 | -133 | -97 | -120 | -138 | -119 | -474 | |
| 1.3 | 0.5 | 0.6 | 0.7 | 0.8 | 0.8 | 0.9 | 1.0 | 0.9 | 1.0 | 0.9 | 0.9 | 0.9 | 1.0 | 0.9 | 1.0 | 1.8 | 0.8 | 0.8 | 1.0 | -0.4 | 1.0 | 2.0 | 2.0 | 3.4 | 2.0 | 2.0 | 1.0 | 3.0 | 3.0 | 2.0 | 2.0 | 3.0 | 3.0 | 2.0 | 2.0 | 3.0 | 2.0 | 3.0 | 10 | |
| – | 0.1 | 0.1 | 0.1 | 0.2 | 0.7 | 1.1 | 1.0 | 1.1 | 1.7 | 2.1 | 2.7 | 2.4 | 3.5 | 4.5 | 6.0 | 7.9 | 13 | 13 | 15 | 14 | 17 | 15 | 16 | 17 | 19 | 18 | 18 | 18 | 20 | 20 | 19 | 17 | 16 | 15 | 14 | 15 | 19 | 15 | 63 | |
| 0.1 | 0.1 | 0.2 | 0.3 | 0.8 | 0.8 | -0.1 | 1.2 | 1.4 | 2.1 | 2.5 | 3.1 | 2.4 | 3.5 | 4.5 | 6.0 | 7.9 | 13 | 14 | 16 | 14 | 19 | 16 | 15 | 17 | 20 | 18 | 16 | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -3.0 | 1.9 | -2.2 | 27 | -1.9 | 1.8 | -2.1 | 3.6 | -1.5 | 5.7 | -8.4 | 4.3 | -7.7 | 16 | 207 | -8.0 | -8.3 | -14 | 6.7 | -360 | 697 | -18 | -35 | -21 | -38 | 13 | -9.0 | -24 | -37 | -19 | 101 | -23 | -37 | -148 | 21 | -30 | -31 | -47 | -87 | |
| 4.1 | 2.1 | 2.2 | 0.8 | 0.3 | 1.1 | 1.3 | 1.1 | 0.3 | 0.6 | 0.6 | 0.6 | 0.2 | 0.2 | 0.3 | 1.1 | 1.5 | 3.6 | 6.1 | 7.9 | 8.5 | 3.0 | 7.0 | 2.0 | 0.4 | 3.0 | 5.0 | 10 | 6.0 | 4.0 | 0.0 | 1.0 | 1.0 | 1.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | 1.0 | |
| -39 | -16 | -3.2 | 13 | -42 | -16 | -16 | -83 | 2.5 | 14 | 27 | 30 | -12 | 40 | -87 | -387 | -0.2 | 63 | 3.0 | -89 | 19 | -268 | -215 | 23 | 47 | 129 | 26 | 11 | 28 | -169 | 63 | -29 | 51 | 32 | 137 | 79 | -182 | 114 | 52 | 63 | |
| – | – | – | – | – | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.3 | 0.0 | 0.6 | – | 0.9 | 126 | -1.1 | 0.0 | 129 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 329 | 0.0 | 0.0 | 1.9 | 0.0 | 1.3 | 220 | 9.9 | 4.3 | 2.5 | – | 1.0 | 23 | – | – | – | -1.0 | 1.0 | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 47 | 0.0 | – | – | 0.0 | 0.0 | – | – | – | |
| 70 | 0.0 | 0.6 | 0.2 | 107 | 129 | -1.1 | 0.0 | 0.8 | 0.0 | 0.6 | 0.0 | 0.5 | 0.6 | 329 | 108 | 1.7 | 222 | 2.2 | 1.3 | 12 | 15 | 4.0 | 3.0 | 11 | 1.0 | 23 | 6.0 | 3.0 | 229 | 2.0 | 48 | -2.0 | 142 | 52 | 8.0 | 286 | 3.0 | 16 | 313 | |
| 18 | -26 | -9.5 | -11 | 80 | 100 | -28 | -95 | -3.8 | -2.6 | 7.6 | 2.9 | -21 | 9.4 | 218 | -63 | -48 | 219 | -69 | -141 | -32 | 401 | -276 | -55 | -12 | 32 | -8.0 | -46 | -57 | 58 | -29 | 45 | -51 | 42 | 56 | -10 | -16 | -21 | -51 | -98 | |
| – | -12 | -9.1 | -25 | 15 | -14 | -12 | -13 | -7.4 | -17 | -20 | -28 | -9.7 | -31 | -24 | 215 | -51 | -70 | -80 | -62 | -71 | 651 | -72 | -83 | -70 | -101 | -62 | -73 | -94 | -6.0 | -94 | 25 | -101 | -133 | -133 | -97 | -121 | -138 | -119 | -475 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.